Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Interest Income

Income earned on cash, deposits, and investments held by the company.

Prothena Corporation plcNASDAQ: PRTA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $2.42M fell 44.4% year over year, ahead of the -46.9% change in trailing-twelve-month interest income. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at +30.6% a year.

Context

  • Interest income amounted to 146.0% of revenue in FY2025, up 126.9 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -44.4% holds above the trailing-twelve-month pace of -46.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.42M-8.7% QoQ
Last fiscal yearDec 2025
$14.14M-45.2% YoY
LTMMar 2026
$12.21M-46.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.4%——
1 year-45.2%——
3-year CAGR+30.6%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
14.14M USD
Year-over-year change
-45.2%
4-year CAGR
+328.3%

Interest Income vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -46.9% is the 3rd highest of 8, against a peer median of -52.7%.
  • Interest income amounts to 21.1% of revenue for PRTA, versus a peer median of 36.6%.
PRTA Competitors
Interest Income for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$132M USD+53.0%-0.6%1.3%
DNLIDenali Therapeutics Inc.LTM Jun 2026$28.36M USD-48.1%+42.7%786.9%
PRTAProthena Corporation plcLTM Mar 2026$12.21M USD-46.9%+30.6%21.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$6.07M USD-63.6%+22.3%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$6.04M USD-52.7%+46.0%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.36M USD-34.9%+70.3%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.36M CHF-58.3%+200.1%36.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
ANNXAnnexon, Inc.LTM Mar 2026-$1.14M USD-107.3%+38.6%—
Peer median (excluding PRTA) —-52.7%+42.7%36.6%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.